New National Medical AI Data Security Standard Seeks Drafting Partners

Artificial intelligence is rapidly integrating with healthcare, creating unprecedented strategic opportunities. The National Health Commission and four other ministries have issued implementation guidelines that aim to establish high‑quality datasets and trusted data spaces by 2027, while market forecasts predict China’s medical AI market will grow from 8.8 billion CNY in 2023 to 315.7 billion CNY by 2033.

Despite policy support and market enthusiasm, the scaling of medical AI is fundamentally constrained by data security and privacy concerns. Medical data are highly sensitive, and AI pipelines—covering model development, training, deployment and inference—amplify risks of leakage, tampering and misuse, potentially leading to severe clinical, ethical and legal consequences.

In response, the China Chamber of Commerce for Electronics Industry, the Zhihhe Standards Center, the National Drug Administration’s Information Center and Ant Group jointly drafted China’s first group standard titled "Medical Artificial Intelligence Application Data Security and Privacy Protection Specification" . The standard provides a comprehensive operational framework that covers data classification, lifecycle security management, privacy‑preserving technologies and multi‑party responsibility delineation.

The standard proposes four key solutions:

Transform the “black box” into a “transparent box” : embed security requirements throughout the data lifecycle—from collection to model retirement—to achieve process‑level risk control and visibility.

Balance data circulation with safety : define technical and acceptance criteria for data de‑identification, anonymization, and federated learning, enabling data to flow without leaving its domain while preserving value.

Clarify boundaries and strengthen evaluation : specify responsibilities and assessment points for privacy‑computing techniques, filling the gap in compliance guidance for emerging technologies.

Define roles and build trust : detail multi‑party role definitions and provide responsibility matrices for typical collaboration models, reducing coordination costs and fostering a trustworthy industry ecosystem.

Participating in the drafting process offers several benefits: official certification from the China Chamber of Commerce, the opportunity to embed proprietary solutions into the national standard, a comprehensive compliance guide that reduces R&D and market‑entry risks, and direct engagement with regulators and leading technology firms.

The call now invites all levels of medical institutions, medical device manufacturers, biotech companies, AI and data service providers, cybersecurity firms, and legal/compliance organizations to contribute to this pivotal standard.